摘要
目的研究胸腺肽注射液辅助化疗对卵巢癌患者CD3^+、CD4^+、NK细胞等指标的影响。方法2013年7月~2016年8月,选取我院收治的卵巢癌患者98例进行研究。以数字法将所有患者分为观察组、对照组,每组49例。观察组患者实施胸腺肽注射液辅助化疗治疗,对照组实施化疗,比较两组患者的CD3^+、CD4^+、NK细胞水平等指标。结果治疗后,观察组的优良率为95.92%,显著高于对照组的79.59%,差异有统计学意义(P<0.05)。治疗后,观察组的CD3^+、CD4^+、NK细胞水平均显著高于对照组,差异有统计学意义(P<0.01)。与治疗前比较,两组治疗后的白细胞计数、中性粒细胞计数以及血红蛋白数量均有所下降,且观察组白细胞计数、中性粒细胞计数的改善程度显著优于对照组,差异有统计学意义(P<0.01)。结论胸腺肽注射液辅助化疗对卵巢癌患者进行治疗,能够有效改善CD3^+、CD4^+、NK细胞水平,调节患者外周血象水平,提高治疗效果。
Objective To study the influence of Thymopeptide Enteric Injection adjuvant chemotherapy on CD3+,CD4+,NK cell level in patients with ovarian cancer.Methods From July 2013 to August 2016,98 patients with ovarian carcinoma treated in our hospital were studied,and they were divided into observation group and control group by using digital method,and there were 49 cases in each group.The patients in the observation group were given Thymopeptide Enteric Injection adjuvant chemotherapy,while the control group was given chemotherapy.CD3^+,CD4^+,NK cell level and so on between two groups were compared.Results After treatment,the excellent and good rate of the observation group was95.92%,which was significantly higher than that of the control group(79.59%),and the difference was statistically significant(P〈0.05).After treatment,the level of CD3^+,CD4^+,and NK in the observation group were significantly higher than those in the control group,the difference was statistically significant(P〈0.01).Compared with before treatment,he white blood cell count,neutrophil count and the number of hemoglobin decreased in the two groups,and the improvement degree of WBC count and neutrophil count in the observation group was significantly better than that in the control group,the difference was statistically significant(P〈0.01).Conclusion Thymopeptide Enteric Injection adjuvant chemotherapy treating patients with ovarian cancer can improve effectively CD3^+,CD4^+,and NK cell level,regulate the peripheral hemogram of the patients,improve the therapeutic effect.
作者
魏淑青
史宇霞
WEI Shu-qing SHI Yu-xia(Department of Internal Medicine-Oncology,Shanxi Tumor Hospital,Taiyuan 030013,China Department of Orthopaedics,Shanxi Tumor Hospital,Taiyuan 030013,China)
出处
《中国当代医药》
2017年第17期63-65,共3页
China Modern Medicine